Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29168
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWanlapakorn, N.-
dc.contributor.authorMaertens, K.-
dc.contributor.authorPeunpa, J.-
dc.contributor.authorTRAN, Mai Phuong Thao-
dc.contributor.authorHENS, Niel-
dc.contributor.authorVan Damme, P.-
dc.contributor.authorThiriard, A.-
dc.contributor.authorRaze, D.-
dc.contributor.authorLocht, C.-
dc.contributor.authorPoovorawan, Y.-
dc.contributor.authorLeuridan, E.-
dc.date.accessioned2019-09-12T12:54:25Z-
dc.date.available2019-09-12T12:54:25Z-
dc.date.issued2020-
dc.identifier.citationClinical infectious diseases, 71 (1), p. 72-80-
dc.identifier.issn1058-4838-
dc.identifier.urihttp://hdl.handle.net/1942/29168-
dc.description.abstractBackground The blunting effect of maternal pertussis immunization during pregnancy on infant antibody responses induced by whole cell pertussis (wP) vaccination is not well-defined. Methods This randomized controlled trial (NCT02408926) followed term infants born to mothers vaccinated with tetanus-diphtheria-acellular pertussis (Tdap)-vaccine during pregnancy in Thailand. Infants received either acellular pertussis (aP)- or wP-containing vaccine at 2, 4, 6 and 18 months of age. A comparison group comprised wP-vaccinated children born to mothers not vaccinated during pregnancy. Antibodies against pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (PRN) were evaluated using commercial enzyme-linked immunosorbent assays (ELISA). Functionality of antibodies against B. pertussis was measured using B. pertussis growth inhibition assay (BGIA). Results After maternal Tdap vaccination, 158 infants vaccinated with aP-containing vaccines possessed higher antibody levels (p < 0.001) against all tested B. pertussis antigens post-priming compared to 157 infants receiving wP-containing vaccines. At one-month post-booster, only anti-FHA and anti-PRN antibodies were still significantly higher (p < 0.001) in the aP group. Significantly higher anti-PT and anti-FHA (p < 0.001), but not anti-PRN IgG, were observed among 69 wP-vaccinated infants born to control mothers compared to wP-vaccinated infants of Tdap-vaccinated mothers after primary and booster vaccination. The antibody functionality was higher in all wP vaccinated infants at all times. Conclusions Maternal Tdap vaccination inhibited more pertussis-specific responses in wP vaccinated infants compared to aP vaccinated infants, and the control group of unvaccinated women had highest pertussis-specific responses, persisting until after the booster dose. Antibody functionality was better in the wP groups.-
dc.description.sponsorshipThrasher Research Fund Award (EWAT 12348) Thailand Research Fund (TRF) (IRG5780015) NSTDA Center of Excellence in Clinical Virology (GCE 58-014-30-004) National Vaccine Institute Department of Pediatrics, Faculty of Medicine, Chulalongkorn University Region Auvergne-Rhone-Alpes Region Bourgogne-Franche-Comte Region Hauts-de-France Region Nouvelle-Aquitaine Institut National de la Sante et de la Recherche Medicale (Inserm) FWO (FWO 12R5719N) European Research Council under the European Union's Horizon 2020 research and innovation program (682540-TransMID) Ratchadaphiseksomphot Endowment Fund-
dc.language.isoen-
dc.publisherOXFORD UNIV PRESS INC-
dc.rightsThe Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)-
dc.subject.otherpertussis-
dc.subject.otherpregnancy-
dc.subject.othermaternal immunization-
dc.subject.otherhumoral immune response-
dc.subject.otherfunctionality-
dc.titleQuantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial-
dc.typeJournal Contribution-
dc.identifier.epage80-
dc.identifier.issue1-
dc.identifier.spage72-
dc.identifier.volume71-
local.bibliographicCitation.jcatA1-
dc.description.notesTopic: action potentials pregnancy atrioventricular accessory pathway alkaline phosphatase alpha-2 antiplasmin immunization infant mothers pertussis vaccine randomization vaccination vaccines antibodies pertussis-
local.publisher.placeJOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA-
dc.relation.references1. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev 2016; 29(3): 449-86. 2. WHO. Pertussis vaccines: WHO position paper - August 2015. Available at: https://www.who.int/wer/2015/wer9035.pdf?ua=1. Accessed 17/05/2019. 3. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. The Lancet 2014; 384(9953): 1521-8. 4. Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; 60(3): 333-7. 5. Vizzotti C, Juarez MV, Bergel E, et al. Impact of a maternal immunization program against pertussis in a developing country. Vaccine 2016; 34(50): 6223-8. 6. ACIP. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morbidity and mortality weekly report 2013; 62(7): 131-5. 7. Ahmad SM, Alam J, Afsar NA, et al. Comparisons of the effect of naturally acquired maternal pertussis antibodies and antenatal vaccination induced maternal tetanus antibodies on infant's antibody secreting lymphocyte responses and circulating plasma antibody levels. Hum Vaccin Immunother 2016; 12(4): 886-93. 8. Booy R, Aitken SJ, Taylor S, et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 1992; 339(8792): 507-10. 9. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995; 96(3 Pt 2): 580-4. 10. Maertens K, Cabore RN, Huygen K, et al. Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. Vaccine 2016; 34(31): 3613-9. 11. Maertens K, Hoang TT, Nguyen TD, et al. The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; 63(suppl 4): S197-S204. 12. Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014; 311(17): 1760-9. 13. Halperin SA, Langley JM, Ye L, et al. A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018; 67(7): 1063-71. 14. WHO. WHO SAGE pertussis working group background paper SAGE April 2014. Available at: https://www.who.int/immunization/sage/meetings/2014/april/1_Pertussis_background_FINAL4_web.pdf. Accessed 17/05/2019. 15. Aftandelians R, Connor JD. Bactericidal antibody in serum during infection with Bordetalla pertussis. The Journal of infectious diseases 1973; 128(4): 555-8. 16. Weingart CL, Keitel WA, Edwards KM, Weiss AA. Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect Immun 2000; 68(12): 7175-9. 17. Weiss AA, Patton AK, Millen SH, Chang SJ, Ward JI, Bernstein DI. Acellular pertussis vaccines and complement killing of Bordetella pertussis. Infect Immun 2004; 72(12): 7346-51. 18. Wanlapakorn N, Ngaovithunvong V, Thongmee T, Vichaiwattana P, Vongpunsawad S, Poovorawan Y. Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination. PLoS One 2016; 11(2): e0148338. 19. The bureau of Epidemiology. The Ministry of Public Health T. National Disease Surveillance (Report 506), Bureau of epidemiology, Ministry of public health, Thailand. Available at: http://www.boe.moph.go.th/Annual/AESR2013/annual/Pertussis.pdf. Accessed 17/05/2019. 20. Wanlapakorn N, Maertens K, Chaithongwongwatthana S, et al. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women. Vaccine 2018. 21. Wanlapakorn N, Thongmee T, Vichaiwattana P, Leuridan E, Vongpunsawad S, Poovorawan Y. Antibodies to Bordetella pertussis antigens in maternal and cord blood pairs: a Thai cohort study. PeerJ 2017; 5: e4043. 22. Ibrahim R, Ali SA, Kazi AM, et al. Impact of maternally derived pertussis antibody titers on infant whole-cell pertussis vaccine response in a low income setting. Vaccine 2018; 36(46): 7048-53. 23. Coutte L, Locht C. Investigating pertussis toxin and its impact on vaccination. Future Microbiol 2015; 10(2): 241-54. 24. Nguyen AW, Wagner EK, Laber JR, et al. A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough. Sci Transl Med 2015; 7(316): 316ra195. 25. Kapil P, Papin JF, Wolf RF, Zimmerman LI, Wagner LD, Merkel TJ. Maternal Vaccination With a Monocomponent Pertussis Toxoid Vaccine Is Sufficient to Protect Infants in a Baboon Model of Whooping Cough. The Journal of infectious diseases 2018; 217(8): 1231-6. 26. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003; 21(25-26): 3542-9. 27. Campbell H. An update on the maternal pertussis immunization programme in England. In: 12th International Symposium on Bordetella. Brussels, Belgium, 2019. 28. Vermeulen F, Verscheure V, Damis E, et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin Vaccine Immunol 2010; 17(2): 258-62. 29. Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum Vaccin 2008; 4(5): 328-40. 30. WHO. WHO Technical Report Series No 941. Annex 6: Recommendations for whole-cell pertussis vaccine. Available at: https://www.who.int/biologicals/publications/trs/areas/vaccines/whole_cell_pertussis/Annex%206%20whole%20cell%20pertussis.pdf?ua=1. Accessed 26/07/2019. 31. Lambert LC. Pertussis vaccine trials in the 1990s. The Journal of infectious diseases 2014; 209 Suppl 1: S4-9. 32. Ladhani SN, Andrews NJ, Southern J, et al. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; 61(11): 1637-44. 33. Feunou PF, Mielcarek N, Locht C. Reciprocal interference of maternal and infant immunization in protection against pertussis. Vaccine 2016; 34(8): 1062-9. 34. Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 2012; 5(5): 485-500. 35. Locht C, Coutte L, Mielcarek N. The ins and outs of pertussis toxin. Febs j 2011; 278(23): 4668-82.-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.relation.h2020682540-TransMID-
dc.identifier.doi10.1093/cid/ciz778-
dc.identifier.pmid31418814-
dc.identifier.isiWOS:000551523900014-
dc.identifier.urlhttps://doi.org/10.1093/cid/ciz778-
dc.identifier.eissn1537-6591-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.fullcitationWanlapakorn, N.; Maertens, K.; Peunpa, J.; TRAN, Mai Phuong Thao; HENS, Niel; Van Damme, P.; Thiriard, A.; Raze, D.; Locht, C.; Poovorawan, Y. & Leuridan, E. (2020) Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. In: Clinical infectious diseases, 71 (1), p. 72-80.-
item.accessRightsOpen Access-
item.validationecoom 2021-
item.contributorWanlapakorn, N.-
item.contributorMaertens, K.-
item.contributorPeunpa, J.-
item.contributorTRAN, Mai Phuong Thao-
item.contributorHENS, Niel-
item.contributorVan Damme, P.-
item.contributorThiriard, A.-
item.contributorRaze, D.-
item.contributorLocht, C.-
item.contributorPoovorawan, Y.-
item.contributorLeuridan, E.-
crisitem.journal.issn1058-4838-
crisitem.journal.eissn1537-6591-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
auteurversie_CID_Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born.pdfPeer-reviewed author version922.25 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

33
checked on May 8, 2024

Page view(s)

78
checked on May 20, 2022

Download(s)

480
checked on May 20, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.